Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates

A. J. Japour, D. L. Mayers, V. A. Johnson, D. R. Kuritzkes, Laurel A Beckett, J. M. Arduino, J. Lane, R. J. Black, P. S. Reichelderfer, R. T. D'Aquila, C. S. Crumpacker, L. Abrams, F. McCutchan, D. Burke, L. Gardner, C. Roberts, R. Chung, C. Hicks, E. Shellie

Research output: Contribution to journalArticle

248 Citations (Scopus)

Abstract

A standardized antiviral drug susceptibility assay for clinical human immunodeficiency virus type 1 (HIV-1) isolates has been developed for use in clinical trials. The protocol is a two-step procedure that first involves cocultivation of patient infected peripheral blood mononuclear cells (PBMC) with seronegative phytohemagglutinin-stimulated donor PBMC to obtain an HIV- 1 stock. The virus stock is titrated for viral infectivity (50% tissue culture infective dose) by use of serial fourfold virus dilutions in donor PBMC. A standardized inoculum of 1,000 50% tissue culture infective doses per 106 cells is used in the second step of the procedure to acutely infect seronegative donor PBMC in a 7-day microtiter plate assay with triplicate wells containing zidovudine (ZDV) concentrations ranging from 0 to 5.0 μM. The ZDV 50% inhibitory concentrations (IC50) for reference ZDV-susceptible and ZDV-resistant HIV-1 isolates ranged from 0.002 to 0.113 μM and from 0.15 to >5.0 μM, respectively. Use of this consensus protocol reduced interlaboratory variability for ZDV IC50 determinations with reference HIV- 1 isolates. Among eight laboratories, the coefficient of variation ranged from 0.85 to 1.25 with different PBMC protocols and was reduced to 0.39 to 0.98 with the standardized assay. Among the clinical HIV-1 isolates assayed by the standardized drug susceptibility assay, the median ZDV IC50 increased gradually with more ZDV therapy. This protocol provides an efficient and reproducible means to assess the in vitro susceptibility to antiretroviral agents of virtually all clinical HIV-1 isolates.

Original languageEnglish (US)
Pages (from-to)1095-1101
Number of pages7
JournalAntimicrobial Agents and Chemotherapy
Volume37
Issue number5
StatePublished - 1993
Externally publishedYes

Fingerprint

Zidovudine
HIV-1
Blood Cells
Cell Culture Techniques
Inhibitory Concentration 50
Pharmaceutical Preparations
Tissue Donors
Anti-Retroviral Agents
Viruses
Phytohemagglutinins
Coculture Techniques
Antiviral Agents
Clinical Trials

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. / Japour, A. J.; Mayers, D. L.; Johnson, V. A.; Kuritzkes, D. R.; Beckett, Laurel A; Arduino, J. M.; Lane, J.; Black, R. J.; Reichelderfer, P. S.; D'Aquila, R. T.; Crumpacker, C. S.; Abrams, L.; McCutchan, F.; Burke, D.; Gardner, L.; Roberts, C.; Chung, R.; Hicks, C.; Shellie, E.

In: Antimicrobial Agents and Chemotherapy, Vol. 37, No. 5, 1993, p. 1095-1101.

Research output: Contribution to journalArticle

Japour, AJ, Mayers, DL, Johnson, VA, Kuritzkes, DR, Beckett, LA, Arduino, JM, Lane, J, Black, RJ, Reichelderfer, PS, D'Aquila, RT, Crumpacker, CS, Abrams, L, McCutchan, F, Burke, D, Gardner, L, Roberts, C, Chung, R, Hicks, C & Shellie, E 1993, 'Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates', Antimicrobial Agents and Chemotherapy, vol. 37, no. 5, pp. 1095-1101.
Japour, A. J. ; Mayers, D. L. ; Johnson, V. A. ; Kuritzkes, D. R. ; Beckett, Laurel A ; Arduino, J. M. ; Lane, J. ; Black, R. J. ; Reichelderfer, P. S. ; D'Aquila, R. T. ; Crumpacker, C. S. ; Abrams, L. ; McCutchan, F. ; Burke, D. ; Gardner, L. ; Roberts, C. ; Chung, R. ; Hicks, C. ; Shellie, E. / Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. In: Antimicrobial Agents and Chemotherapy. 1993 ; Vol. 37, No. 5. pp. 1095-1101.
@article{6efaf10e71094c1caf59f7de51f4ca48,
title = "Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates",
abstract = "A standardized antiviral drug susceptibility assay for clinical human immunodeficiency virus type 1 (HIV-1) isolates has been developed for use in clinical trials. The protocol is a two-step procedure that first involves cocultivation of patient infected peripheral blood mononuclear cells (PBMC) with seronegative phytohemagglutinin-stimulated donor PBMC to obtain an HIV- 1 stock. The virus stock is titrated for viral infectivity (50{\%} tissue culture infective dose) by use of serial fourfold virus dilutions in donor PBMC. A standardized inoculum of 1,000 50{\%} tissue culture infective doses per 106 cells is used in the second step of the procedure to acutely infect seronegative donor PBMC in a 7-day microtiter plate assay with triplicate wells containing zidovudine (ZDV) concentrations ranging from 0 to 5.0 μM. The ZDV 50{\%} inhibitory concentrations (IC50) for reference ZDV-susceptible and ZDV-resistant HIV-1 isolates ranged from 0.002 to 0.113 μM and from 0.15 to >5.0 μM, respectively. Use of this consensus protocol reduced interlaboratory variability for ZDV IC50 determinations with reference HIV- 1 isolates. Among eight laboratories, the coefficient of variation ranged from 0.85 to 1.25 with different PBMC protocols and was reduced to 0.39 to 0.98 with the standardized assay. Among the clinical HIV-1 isolates assayed by the standardized drug susceptibility assay, the median ZDV IC50 increased gradually with more ZDV therapy. This protocol provides an efficient and reproducible means to assess the in vitro susceptibility to antiretroviral agents of virtually all clinical HIV-1 isolates.",
author = "Japour, {A. J.} and Mayers, {D. L.} and Johnson, {V. A.} and Kuritzkes, {D. R.} and Beckett, {Laurel A} and Arduino, {J. M.} and J. Lane and Black, {R. J.} and Reichelderfer, {P. S.} and D'Aquila, {R. T.} and Crumpacker, {C. S.} and L. Abrams and F. McCutchan and D. Burke and L. Gardner and C. Roberts and R. Chung and C. Hicks and E. Shellie",
year = "1993",
language = "English (US)",
volume = "37",
pages = "1095--1101",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "5",

}

TY - JOUR

T1 - Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates

AU - Japour, A. J.

AU - Mayers, D. L.

AU - Johnson, V. A.

AU - Kuritzkes, D. R.

AU - Beckett, Laurel A

AU - Arduino, J. M.

AU - Lane, J.

AU - Black, R. J.

AU - Reichelderfer, P. S.

AU - D'Aquila, R. T.

AU - Crumpacker, C. S.

AU - Abrams, L.

AU - McCutchan, F.

AU - Burke, D.

AU - Gardner, L.

AU - Roberts, C.

AU - Chung, R.

AU - Hicks, C.

AU - Shellie, E.

PY - 1993

Y1 - 1993

N2 - A standardized antiviral drug susceptibility assay for clinical human immunodeficiency virus type 1 (HIV-1) isolates has been developed for use in clinical trials. The protocol is a two-step procedure that first involves cocultivation of patient infected peripheral blood mononuclear cells (PBMC) with seronegative phytohemagglutinin-stimulated donor PBMC to obtain an HIV- 1 stock. The virus stock is titrated for viral infectivity (50% tissue culture infective dose) by use of serial fourfold virus dilutions in donor PBMC. A standardized inoculum of 1,000 50% tissue culture infective doses per 106 cells is used in the second step of the procedure to acutely infect seronegative donor PBMC in a 7-day microtiter plate assay with triplicate wells containing zidovudine (ZDV) concentrations ranging from 0 to 5.0 μM. The ZDV 50% inhibitory concentrations (IC50) for reference ZDV-susceptible and ZDV-resistant HIV-1 isolates ranged from 0.002 to 0.113 μM and from 0.15 to >5.0 μM, respectively. Use of this consensus protocol reduced interlaboratory variability for ZDV IC50 determinations with reference HIV- 1 isolates. Among eight laboratories, the coefficient of variation ranged from 0.85 to 1.25 with different PBMC protocols and was reduced to 0.39 to 0.98 with the standardized assay. Among the clinical HIV-1 isolates assayed by the standardized drug susceptibility assay, the median ZDV IC50 increased gradually with more ZDV therapy. This protocol provides an efficient and reproducible means to assess the in vitro susceptibility to antiretroviral agents of virtually all clinical HIV-1 isolates.

AB - A standardized antiviral drug susceptibility assay for clinical human immunodeficiency virus type 1 (HIV-1) isolates has been developed for use in clinical trials. The protocol is a two-step procedure that first involves cocultivation of patient infected peripheral blood mononuclear cells (PBMC) with seronegative phytohemagglutinin-stimulated donor PBMC to obtain an HIV- 1 stock. The virus stock is titrated for viral infectivity (50% tissue culture infective dose) by use of serial fourfold virus dilutions in donor PBMC. A standardized inoculum of 1,000 50% tissue culture infective doses per 106 cells is used in the second step of the procedure to acutely infect seronegative donor PBMC in a 7-day microtiter plate assay with triplicate wells containing zidovudine (ZDV) concentrations ranging from 0 to 5.0 μM. The ZDV 50% inhibitory concentrations (IC50) for reference ZDV-susceptible and ZDV-resistant HIV-1 isolates ranged from 0.002 to 0.113 μM and from 0.15 to >5.0 μM, respectively. Use of this consensus protocol reduced interlaboratory variability for ZDV IC50 determinations with reference HIV- 1 isolates. Among eight laboratories, the coefficient of variation ranged from 0.85 to 1.25 with different PBMC protocols and was reduced to 0.39 to 0.98 with the standardized assay. Among the clinical HIV-1 isolates assayed by the standardized drug susceptibility assay, the median ZDV IC50 increased gradually with more ZDV therapy. This protocol provides an efficient and reproducible means to assess the in vitro susceptibility to antiretroviral agents of virtually all clinical HIV-1 isolates.

UR - http://www.scopus.com/inward/record.url?scp=0027270541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027270541&partnerID=8YFLogxK

M3 - Article

C2 - 8517697

AN - SCOPUS:0027270541

VL - 37

SP - 1095

EP - 1101

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 5

ER -